{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:06:59Z","timestamp":1780038419604,"version":"3.53.1"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515140141"],"award-info":[{"award-number":["2023A1515140141"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100195"],"award-info":[{"award-number":["82100195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2025GP004"],"award-info":[{"award-number":["2025GP004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105310","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:59:15Z","timestamp":1774972755000},"page":"105310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent advancements of neoadjuvant strategies in locally advanced rectal cancer"],"prefix":"10.1016","volume":"223","author":[{"given":"Juju","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-0164","authenticated-orcid":false,"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00384-025-04901-1","article-title":"Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: long-term results of a randomized controlled trial","volume":"40","author":"Aghili","year":"2025","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.critrevonc.2026.105310_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103015","article-title":"Advances in the management of locally advanced rectal cancer: a shift toward a patient-centred approach to balance outcomes and quality of life","volume":"140","author":"Airoldi","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1186\/s12885-025-14482-5","article-title":"Neoadjuvant chemoradiotherapy with or without PD-1\/PD-L1 inhibitors in locally advanced rectal cancer: a systematic review and meta-analysis","volume":"25","author":"Ansab","year":"2025","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105310_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jamaoncol.2025.2026","article-title":"Total neoadjuvant therapy for locally advanced rectal cancer","volume":"11","author":"Audisio","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib5","article-title":"MRI to guide clinical management of rectal cancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)\u2014PART I primary staging","author":"Ayuso","year":"2026","journal-title":"Eur. Radiol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105310_bib6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105310_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2024.10.827","article-title":"A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial","volume":"36","author":"Baron","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105310_bib8","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1245\/s10434-025-18058-2","article-title":"Local regrowth after a watch-and-wait strategy for middle and low rectal cancer: is organ preservation still feasible?","volume":"32","author":"Boubaddi","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105310_bib9","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jso.27839","article-title":"Omission of chemoradiation in locally advanced rectal adenocarcinoma: evaluation of PROSPECT in a national database","volume":"130","author":"Buchheit","year":"2024","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib10","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/j.annonc.2023.09.1786","article-title":"595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)","volume":"34","author":"Capdevila Castillon","year":"2023","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105310_bib11","article-title":"Comparing local excision with watch and wait for the management of rectal cancer patients responding to neoadjuvant chemoradiotherapy: Composite endpoint analysis using the win ratio","volume":"27","author":"Capelli","year":"2025","journal-title":"Colorectal Dis. Off. J. Assoc. Coloproctology Gt. Br. Irel."},{"key":"10.1016\/j.critrevonc.2026.105310_bib12","doi-asserted-by":"crossref","first-page":"S432","DOI":"10.1016\/j.annonc.2023.09.1790","article-title":"599P R-IMMUNE: A phase Ib\/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)","volume":"34","author":"Carrasco","year":"2023","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105310_bib13","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative Management of Mismatch Repair-Deficient Tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"New Engl. J. Med."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105310_bib14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00384-025-04993-9","article-title":"Development and validation of machine-learning model based on dynamic tumor markers in predicting pathological complete response after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a multicenter cohort study","volume":"40","author":"Chen","year":"2025","journal-title":"Int. J. Colorectal Dis."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105310_bib16","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1007\/s00330-025-11439-x","article-title":"MRI-based scoring systems for selective lateral lymph node dissection in locally advanced low rectal cancer after neoadjuvant chemoradiotherapy","volume":"35","author":"Cho","year":"2025","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000006942","article-title":"Two-week course versus conventionally fractionated preoperative chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer (Twoarc Trial): a phase iii randomized clinical trial","author":"Choi","year":"2025","journal-title":"Ann. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105310_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00428-024-03974-7","article-title":"Low CXCL11 expression is indicative of poor prognosis in rectal cancer patients undergoing preoperative chemoradiotherapy: a retrospective cohort study","volume":"486","author":"Chou","year":"2025","journal-title":"Virchows Arch. Int. J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12943-025-02232-x","article-title":"Radioresistance in rectal cancer: can nanoparticles turn the tide?","volume":"24","author":"Coelho","year":"2025","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105310_bib20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103312","article-title":"Total neoadjuvant therapy integrating long-course radiotherapy with trifluridine\/tipiracil for locally advanced rectal cancer: a single-arm, multicenter phase 2 trial","volume":"85","author":"Dou","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00384-025-04867-0","article-title":"Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer","volume":"40","author":"Emoto","year":"2025","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.critrevonc.2026.105310_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2025.102252","article-title":"Survival outcomes and pathologic complete response following neoadjuvant chemoradiotherapy versus chemotherapy alone in locally advanced rectal cancer","volume":"61","author":"Erkaya","year":"2025","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112378","article-title":"Predictive model based on mesorectal fat radiomics for pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer","volume":"192","author":"Fan","year":"2025","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib25","article-title":"Immune activation following PD-L1 inhibitor plus chemoradiotherapy in locally advanced rectal cancer: a retrospective, single-arm study","volume":"16","author":"Fan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib26","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.annonc.2024.05.256","article-title":"249P The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and cadonilimab for locally advanced rectal cancer: The preliminary findings of prospective, multicenter phase II trial","volume":"35","author":"Feng","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00384-024-04803-8","article-title":"Predicting treatment response and survival in rectal cancer: insights from 18 FDG-PET\/MRI post-neoadjuvant therapy","volume":"40","author":"Ferri","year":"2025","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.critrevonc.2026.105310_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114291","article-title":"Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO\/ARO\/AIO-12 and the OPRA randomized phase 2 trials","volume":"210","author":"Fokas","year":"2024","journal-title":"European J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105310_bib29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S2468-1253(25)00049-4","article-title":"Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO\/ARO\/AIO-16): an open-label, multicentre, single-arm, phase 2 trial","volume":"10","author":"Gani","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib30","article-title":"Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer","volume":"13","author":"Gao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib31","article-title":"Quality of life and functional outcomes after rectal sparing approaches following neoadjuvant therapy for rectal cancer: a prospective cohort multicentre study","author":"Gavaruzzi","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105310_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.103695","article-title":"Quality-of-life analysis of a phase ii randomised controlled trial comparing three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in locally advanced rectal cancer","volume":"37","author":"Geary","year":"2025","journal-title":"Clin. Oncol."},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105310_bib33","first-page":"TPS3620","article-title":"Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2","volume":"37","author":"George","year":"2019"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105310_bib34","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/DCR.0000000000003839","article-title":"Expanding organ preservation in locally advanced rectal cancer after total neoadjuvant therapy with endoscopic submucosal dissection","volume":"68","author":"Gorgun","year":"2025","journal-title":"Dis. Colon Rectum"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105310_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101824","article-title":"Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial","volume":"8","author":"Grassi","year":"2023","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105310_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-82814-9","article-title":"S100A4 contributes to colorectal carcinoma aggressive behavior and to chemoradiotherapy resistance in locally advanced rectal carcinoma","volume":"14","author":"Harada","year":"2024","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105310_bib38","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/ijc.70040","article-title":"Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer","volume":"157","author":"Haraguchi","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105310_bib39","first-page":"613","article-title":"The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? The British","volume":"69","author":"Heald","year":"1982","journal-title":"J. Surg."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105310_bib40","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","article-title":"Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Hofheinz","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13014-025-02726-4","article-title":"The impact of different neoadjuvant radiotherapy doses on survival outcomes and toxicity in patients with locally advanced rectal cancer","volume":"20","author":"Huang","year":"2025","journal-title":"Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105310_bib42","first-page":"198","article-title":"Multidisciplinary team meeting significantly enhances disease-free survival in stage II-III rectal cancer","volume":"24","author":"Jiang","year":"2025","journal-title":"Clin. Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10151-025-03180-w","article-title":"Increasing age, neural invasion, extramural vascular invasion, and short-course radiotherapy in locally advanced rectal cancer are associated with decreased tumor regression: a retrospective cohort study","volume":"29","author":"Johnsen","year":"2025","journal-title":"Tech. Coloproctology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105310_bib44","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ijrobp.2025.05.018","article-title":"Quality of life after two sequences of total neoadjuvant treatment in patients with locally advanced rectal cancer in the randomized CAO\/ARO\/AIO-12 Phase 2 Trial","volume":"123","author":"Kosmala","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105310_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.27769","article-title":"Dual immune checkpoint inhibition plus neoadjuvant chemoradiotherapy in rectal cancer: a randomized clinical trial","volume":"8","author":"Laengle","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105310_bib46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/DCR.0000000000003586","article-title":"Rectal cancer watch-and-wait management: experience of 545 patients from the US rectal cancer research group","volume":"68","author":"Lai","year":"2025","journal-title":"Dis. Colon Rectum"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-83109-9","article-title":"Prognostic value of pseudotime from texture parameters of FDG PET\/CT in locally advanced rectal cancer with neoadjuvant concurrent chemoradiotherapy","volume":"14","author":"Lee","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00384-024-04801-w","article-title":"Predictive value of rectal MRI variables for pathological complete response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy","volume":"40","author":"Li","year":"2025","journal-title":"Int. J. Colorectal Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00423-025-03746-0","article-title":"Functional outcomes in rectal cancer patients treated with immunotherapy and neoadjuvant therapy: a retrospective analysis","volume":"410","author":"Li","year":"2025","journal-title":"Lange 's Arch. Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105310_bib50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total Neoadjuvant therapy with pd-1 blockade for high-risk proficient mismatch repair rectal cancer","volume":"159","author":"Li","year":"2024","journal-title":"JAMA Surg."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105310_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105310_bib52","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70123","article-title":"Titin gene mutations enhance radiotherapy efficacy via modulation of tumour immune microenvironment in rectum adenocarcinoma","volume":"15","author":"Liu","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105310_bib54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10555-025-10279-x","article-title":"Optimal choice of different neoadjuvant chemoradiotherapies for locally advanced rectal cancer: systematic review and network meta-analysis","volume":"44","author":"Liu","year":"2025","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.critrevonc.2026.105310_bib55","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.annonc.2024.05.259","article-title":"252P Neoadjuvant chemoradiotherapy plus PD-1 blockade for high or very high-risk locally advanced rectal cancer","volume":"35","author":"Liu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2025.108974","article-title":"DG-MSGAT: a biologically-informed differential gene multi-scale graph attention network for predicting neoadjuvant therapy response in rectal cancer","volume":"271","author":"Luo","year":"2025","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib57","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13014-025-02701-z","article-title":"Radiation enteritis associated with temporal sequencing of total neoadjuvant therapy in locally advanced rectal cancer: a preliminary study","volume":"20","author":"Ma","year":"2025","journal-title":"Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105310_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae091","article-title":"Effect of radiotherapy on long-term quality of life in recurrence-free rectal cancer survivors (LaTE study): nationwide inverse probability of treatment-weighted registry-based cohort study and survey","volume":"8","author":"Malik","year":"2024","journal-title":"BJS Open"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105310_bib59","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/SLA.0000000000005780","article-title":"Neoadjuvant chemotherapy with capox versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a phase III Trial","volume":"277","author":"Mei","year":"2023","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2026.105310_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00731","article-title":"Neoadjuvant chemotherapy with capox versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (convert): final results of a phase III Trial","author":"Mei","year":"2026","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-80855-8","article-title":"Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapy","volume":"14","author":"Molinari","year":"2024","journal-title":"Sci. Rep."},{"issue":"7-8","key":"10.1016\/j.critrevonc.2026.105310_bib62","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/ans.70169","article-title":"Total neoadjuvant therapy versus conventional neoadjuvant therapy for rectal cancer: cost analysis in a public healthcare system","volume":"95","author":"Murshed","year":"2025","journal-title":"ANZ J. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib63","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1245\/s10434-024-16056-4","article-title":"Economic evaluation of 'watch and wait' following neoadjuvant therapy in locally advanced rectal cancer: a systematic review","volume":"32","author":"Murshed","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib64","article-title":"Simultaneous integrated boost intensity-modulated radiation therapy targeting clinically involved extramesorectal lymph nodes in locally advanced rectal cancer: A retrospective study","volume":"27","author":"Nayak","year":"2025","journal-title":"Colorectal Dis. Off. J. Assoc. Coloproctology Gt. Br. Irel."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105310_bib65","article-title":"Real-world clinical outcomes of total neoadjuvant therapy followed by total mesorectal excision for locally advanced rectal cancer at a high-volume institution","volume":"51","author":"Ng","year":"2025","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110701","article-title":"Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: a multicenter retrospective study - ATLANTIS part I","volume":"204","author":"Nicosia","year":"2025","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12885-025-13458-9","article-title":"Role of mast cell in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy","volume":"25","author":"Nishi","year":"2025","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105310_bib68","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.21873\/anticanres.17700","article-title":"Response-guided Strategy Based on Induction Chemotherapy Without Routine Use of Radiotherapy for locally advanced rectal cancer","volume":"45","author":"Ogura","year":"2025","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2026.105310_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104921","article-title":"Immune checkpoint inhibitors for dMMR\/MSI localized rectal cancer: a systematic review of treatment strategies","volume":"215","author":"Petrelli","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105310_bib70","article-title":"Contact X-ray brachytherapy in rectal cancer: a systematic review and meta-analysis","volume":"51","author":"Powell","year":"2025","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105310_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf190","article-title":"Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial","volume":"112","author":"Prata","year":"2025","journal-title":"Br. J. Surg."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105310_bib72","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/DCR.0b013e3182a2303e","article-title":"Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial","volume":"56","author":"Pucciarelli","year":"2013","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.critrevonc.2026.105310_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115156","article-title":"A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: transanal endoscopic microsurgery -A multicenter prospective case-control clinical trial by MONT-R","volume":"216","author":"Qiu","year":"2025","journal-title":"European J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105310_bib74","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2465015","article-title":"Combined tumor-associated microbiome and immune gene expression profiling predict response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer","volume":"14","author":"Roesel","year":"2025","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105310_bib76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S2468-1253(19)30410-8","article-title":"Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial","volume":"5","author":"Rullier","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105310_bib77","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105310_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115428","article-title":"Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: the averectal study","volume":"222","author":"Shamseddine","year":"2025","journal-title":"European J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105310_bib79","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1007\/s00464-025-12064-x","article-title":"Hospital operative volume impacts surgical outcomes for patients with T4 rectal cancer following neoadjuvant chemoradiation: a national cancer database analysis","volume":"39","author":"Simon","year":"2025","journal-title":"Surg. Endosc."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105310_bib80","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.ccell.2024.08.003","article-title":"PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer","volume":"42","author":"Somasundaram","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105310_bib81","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijrobp.2025.04.035","article-title":"Acute and late radiation-related toxicity after treatment of locally advanced rectal cancer with intensity modulated radiation therapy compared with 3-dimensional conformal radiation therapy in the RAPIDO trial","volume":"123","author":"Tanaka","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105310_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100807","article-title":"Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II)","volume":"6","author":"Tang","year":"2025","journal-title":"Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib83","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50903","article-title":"Organ preservation and survival by clinical response grade in patients with rectal cancer treated with total neoadjuvant therapy: a secondary analysis of the opra randomized clinical trial","volume":"7","author":"Thompson","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105310_bib84","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1470-2045(25)00286-4","volume":"26","author":"Tian","year":"2025","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib85","doi-asserted-by":"crossref","first-page":"323","DOI":"10.21873\/anticanres.17420","article-title":"Prognostic relevance of immunosuppressive CD155\/TIGIT signaling in locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy","volume":"45","author":"Tsai","year":"2025","journal-title":"Anticancer Res."},{"issue":"10139","key":"10.1016\/j.critrevonc.2026.105310_bib86","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib87","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JS9.0000000000001960","article-title":"Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study","volume":"111","author":"Wang","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105310_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111073","article-title":"Neoadjuvant immunotherapy and chemoradiotherapy for mismatch repair proficient locally advanced rectal cancer: a systematic review and meta-analysis","volume":"211","author":"Wang","year":"2025","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib89","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.1038\/s41598-025-90191-0","article-title":"Prognostic model for log odds of negative lymph node in locally advanced rectal cancer via interpretable machine learning","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105310_bib90","article-title":"Toripalimab, bevacizumab, and irinotecan in dMMR\/MSI locally advanced colorectal cancer: First-stage results from a phase 1b\/2 trial","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105310_bib91","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.24.00681","article-title":"Cost-effectiveness of total neoadjuvant therapy with selective nonoperative management for locally advanced rectal cancer: analysis of data from the organ preservation for rectal adenocarcinoma trial","volume":"43","author":"Widmar","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105310_bib92","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.annonc.2025.01.006","article-title":"Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO\/ARO\/AIO-12 and OPRA randomized phase II trials","volume":"36","author":"Williams","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105310_bib93","first-page":"150","article-title":"Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial","volume":"43","author":"Wu","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105310_bib94","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-0975","article-title":"Organ preservation via immunotherapy-based total neoadjuvant therapy in early low rectal cancer (TORCH-E): a multicenter, open-label, single-arm, phase 2 study","author":"Xia","year":"2025","journal-title":"Clinical Cancer Res. Official J. American Association Cancer Res."},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105310_bib95","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase ii trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72818-w","article-title":"Validation of a genome-based model for adjusting radiotherapy dose (GARD) in patients with locally advanced rectal cancer","volume":"14","author":"Xia","year":"2024","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105310_bib97","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105310_bib98","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41591-024-03360-5","article-title":"Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial","volume":"31","author":"Yang","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib99","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib100","article-title":"Safety and efficacy of individualized modified total neoadjuvant therapy for low locally advanced rectal cancer","volume":"15","author":"Ye","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/DCR.0000000000003395","article-title":"What predicts complete response to total neoadjuvant therapy in locally advanced rectal cancer?","volume":"68","author":"Yilmaz","year":"2025","journal-title":"Dis. Colon Rectum"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105310_bib102","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1007\/s00330-024-11220-6","article-title":"Volumetric histogram analysis of amide proton transfer-weighted imaging for predicting complete tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma","volume":"35","author":"Yuan","year":"2025","journal-title":"Eur. Radiol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105310_bib103","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1097\/JS9.0000000000002262","article-title":"Comparison of the efficacy of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients: meta-analysis of randomized controlled trials","volume":"111","author":"Zeng","year":"2025","journal-title":"Int. J. Surg. (Lond. Engl. )"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105310_bib104","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO-24-01676","article-title":"Neoadjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: updated results of the fowarc study after a median follow-up of 10 years","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105310_bib105","article-title":"Preliminary efficacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in pMMR\/MSS locally advanced rectal cancer (ESTIMATE): A prospective, single-arm, phase II trial","volume":"42","author":"Zhang","year":"2024"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105310_bib106","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae118","article-title":"Number of lymph nodes retrieved in patients with locally advanced rectal cancer after total neoadjuvant therapy: post-hoc analysis from the STELLAR trial","volume":"8","author":"Zhang","year":"2024","journal-title":"BJS Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105310_bib107","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s13304-025-02175-4","article-title":"Survival benefit and impact of adjuvant chemotherapy following neoadjuvant therapy in patients with locally advanced rectal cancer","volume":"77","author":"Zheng","year":"2025","journal-title":"Updates Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105310_bib108","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-090765","article-title":"Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R)","volume":"15","author":"Zhou","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.critrevonc.2026.105310_bib109","doi-asserted-by":"crossref","unstructured":"Zhou, L., Yu, G., Shen, Y., Ding, H., Zheng, K., Wen, R., Jiang, S., Wang, H., Liu, L., Bai, C., Hao, L., Zhang, H., Zhang, W., 2022. The clinical efficacy and safety of neoadjuvant chemoradiation therapy with immunotherapy for the organ preservation of ultra low rectal cancer: A single arm and open label exploratory studye156034016_e1560310.1200\/JCO.2022.40.16_suppl.e15603.","DOI":"10.1200\/JCO.2022.40.16_suppl.e15603"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:00:09Z","timestamp":1780038009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":109,"alternative-id":["S1040842826001976"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105310","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advancements of neoadjuvant strategies in locally advanced rectal cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105310"}}